Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking good here today. Wouldn't surprise me to see a shake in the afternoon, but I think we've said goodbye to the .05's.
I added a few more this morning. 10k will give us the background info we are waiting for on the diagnostics...hopefully including a hard deadline....if that happens, look out.
"The times they are a changin'" around here and for the better.
New and prominent members on the advisory board and possible additions to the diagnostic line!
Good things are coming for AMBS
CEO referred to "additional product lines in the diagnostic" area. He also mentioned that the dilution resulted in a "stronger company with more prospects."
Cerora, Inc is developing its MindReader™ platform to commercialize a non-invasive, accurate, accessible and affordable mobile device to aid in the diagnosis of TBI. This talk with provide an overview of the device along with the “cloud” based neuro diagnostics as a service IT infrastructure. Preliminary findings from a pilot cross sectional clinical study design will be presented.
This was the presented material by Adam Simon at the TBI conference last month. Simon is the Pres/CEO of Cerora. If he is coming on board AMBS, perhaps he is bringing this diagnostic tool as well.
Speculation only.
Read this article on Adam Simon and any long/mid term concerns will fade. In the brain science field, this is "the guy."
http://articles.philly.com/2010-04-27/news/24959186_1_biomarkers-sbir-federal-grant
Most interesting is how he discusses that, "The hardest thing for me was finding good business partners," he says.
"But it's rare to find a like-minded individual who can collaborate as a full-fledged partner and not just a service provider, he says."
Disclosure..the article is a few years old and he is not speaking of Amarantus, but you see the deliberation he takes before connecting himself to an organization as he now has with AMBS.
Actually it could be great news.
Amarantus "owns" the patent rights to MANF. They actually discovered it and have already defended it in a court decision last Fall when someone tried to claim it as well.
If anyone wants to use MANF in the future, they have to go through Amarantus.
Ceregene's clinical results could be great news for MANF/AMBS! I believe that they are expected to be out this month.
It would mean that Ceregene has solved the question of delivery method to the brain! That's where Cogane failed..... Their GDNF factor was orally administered and failed to deliver behavioral improvements along with the clinical improvements..
If Ceregene's trials with neurturin yield real measurable behavioral improvements...it could be a great sign for the success of MANF.
As I understand it neurturin is of the GDNF family(per Wiki)....And since much of AMBS's latest tests have proven how MANF is yielding better results that the GDNF treatments... it would seem logical to me to test MANF in the same manner to compare levels of behavioral improvement.
Interesting new MJF article in AARP magazine
https://www.michaeljfox.org/foundation/news-detail.php?michael-fox-kicks-off-parkinson-awareness-month-with-the-april-issue-of-aarp-the-magazine
Statement is made that:
"At the moment, all eyes are on a promising surgical therapy involving a specialized brain protein called neurturin, which may slow or stop Parkinson's symptoms rather than temporarily mask them. In testing, neurturin has been found to help rejuvenate neurons damaged by Parkinson's, and restore function."
Neurturin belongs to the to the GDNF family and has been in study for longer than MANF.... and has received MJFF grants back to at least 2005, whereas MANF is newer to the game and has only been on the MJFF radar since 2010.
IMO the ceregene results will be an immense predictor for the success of MANF. The GDNF derived Cogaine failed to show measurable behavioral improvement to go with their clinical improvement……but, this is attributed to it being an orally administered drug. The administration of neurturin is surgical, as I assume?? MANF would be.(correct me if wrong?)
AMBS recently released results for both protection and reinnervation have shown that MANF yields significantly better results than those of the GDNF family.
I would expect that positive news for neurturin, being released in April, could be a huge catalyst for MANF in the eyes of science.
Not really sure why we are arguing this point since so much else is happening with MANF and AMBS, but.....
https://www.michaeljfox.org/files/docs/tpp_conf_transcript.pdf
Again, read the doc. page 3.
"Invitations to apply for Stage II of the review process will be sent out no later than mid-December 2012. At that time, the structure for this Second Stage application will be provided. Stage II applications will be then due on February 6, 2013 and we will then take a month or so to review those applications and
expect to announce the awards in May 2013 and to begin funding the grantees in June 2013. "
From: Fall 2012 MJFF Therapeutics Pipeline Program
Informational Conference Call
August 1, 2012
Now...pure hopeful speculation....
the time frame of the infamous "disavowed" PR right around(mid-Dec) when AMBS could have received an invitation to the Stage II
Stage II data was due right around the time(Early Feb) that AMBS pulled together all current data for OneMEd.
At least read the link to MJFF transcript before you two make your statements...
This is for last Falls funding cycle of the new Therep. Process Grant program. The deadline coming up is for the Spring cycle.
I realize it doesn't seem to make sense, but this is still for "last year's" BIG DOG grant money. MJFF's new program has 2 phases in which to qualify. They would have applied last Fall.....all other awards have been announced from that cycle...except for this one because those asked to proceed to phase 2 submitted additional info in Feb.
Pleas just click on the link and read the bottom of page 3....please. Page 3. Bottom.
https://www.michaeljfox.org/files/docs/tpp_conf_transcript.pdf
Not saying that they are getting it...not saying they want it... just putting factual info out there for reference.
BTW-I'm "Disavowing" your comment...oooooo
Time for a post.....
1. Why does everyone insist on using the term "disavow"? The only time I have every heard this used so much is in spy movies and this board.
MJFF did not "disavow" AMBS....I could perhaps accept that they "disavowed" the statement made by AMBS. Big Difference. And a fact that AMBS later acknowledged error of their words.
That series of events revolves around Fall MJFF funding that is yet to be disbursed/awarded, and will not be awarded until end May of this year. (Referring to the time-line I sticky'd and that has been mysteriously removed.
In December, Phase 1 ended and invitations were made to proceed to Phase II.....which will be announced in May.
Therep. Process Grant Time time-line
Once again for the cheap seats...bottom of page 3.
https://www.michaeljfox.org/files/docs/tpp_conf_transcript.pdf
2. So yes, some brokerages allow shorting of these penny's....curious, what is the cost/margin required to do so? I was under the impression that it was huge bucks/share… Not looking to do it, just questioning the credibility of the individual investors suggesting that they are..
3. And for those still harping on the “same old news” for yesterdays PR….it was new news. As pointed out yesterday and a few times today. Study was focused on "proactive" rather than "reactive treatment." Again, Big Difference for marketability
This PR arrived right on time,"end of 1st Qrt. (as indicated by last company announcement)
Next will be the audited results in "2 qrt."(as indicated)
Once audited data has been received......and "only then" IMO, will there be anything related to partnership.ect.
Been here awhile and know what I own....do I look for a new PR everyday....HELL Yeah!
But I also understand when one isn't there.
The new results DO provide new information…although slight.
Unless I’m missing something, the new data was derived from a neuro-protective study...MANF administered, and then damage induced.
Previous data was from a neuro-restorative study...damage induced, and then MANF administered.
Not saying I wouldn’t be happier with a bigger PR about JV, but this is in fact new study data that could imply usage of MANF as both a reactive and proactive treatment.
"'Off-label' use for a variety of 'obsessive compulsive' disorders, including obsessive compulsive posting' of old news, is also being investigated. OCD's are thought to result from a misfiring of the neurons located anterior to the substantia nigra. So on the way in MANF can be....."
Parkinsons, TBI...resent studies have even shown possible uses of MANF as an invitro-treatment of subjects with some intellect but that have succumbed to a irrational patterns of self-righteousness and superiority....along with overtones of douche-baggery.
And Chicago hockey sucks.
Warning:Speculation and intuitive thought.
Another interesting and new article about Banyan that contains inferences to Amarantus.
More and more I'm thinking that while so much focus has been paid to MANF and PD.....the true breakthrough for the company may be in TBI. Amarantus and Banyan have already collaborated on a multi million dollar clinical trail funded by the Dept of Defense.
http://www.fiercebiotech.com/press-releases/banyan-biomarkers-inc-awarded-26-3-million-department-defense-contract-diagnostic-tes
This is where the treatment$$ will come from:TBI treatments for everything from sports injuries to injuries suffered in military service.
http://gainesvillebizreport.com/banyan-biomarkers-revolutionizes-test-for-brain-injury/
"No medication to treat brain injury is on the market today. Banyan is collaborating with a company that is developing a promising treatment, and Banyan is studying some treatments on its own."
Who do you think "a company" could be???
BTW: This is completely aside from incredible Diagnostic Division opportunities!!
Been a good day here..lets finish strong!
That's why it's called an "investment." If you want a weekly hyped POS daytrade ....you're on the wrong board. Plenty of them out there. Go put you money there.
Things are beginning to heat up here....
Show me a stock that has news every single week and I have no doubt that it's a shamwagon creating empty news to fluff their stock value.
Gerald has made his intentions clear to focus on the business and bring it to a reputable level where an uplisting could occur. This takes both stock price...and stock stability.
News isn't out so the stock is down...when the news does finally comes, it will be solid news that will retain and hold the stock value...no more yo-yo. If you hold shares...you'll be glad you did. IMO
Great News!!So another successful and respected person in the medical research community has strengthen ties with AMBS....
Hmmmm should I believe in his intentions and opinions of MANF/Amarantus.....or should I stick with the swayed opinions of some on this board who wouldn't know a test tube from from a shot glass??
Tough call, but I'm going with AMBS!!
It's been a quite week over a lot of the pennies this week....
Everyone needs to have a green beer this weekend and get ready for great things here next week. CPSZ!
Looking for news next week and this thing will take off...
Heeeere we go...feeling great about today!
Warning:Pure Speculation and Hopeful insight...
Disclosure complete.
http://www.marketwatch.com/story/ge-nfl-leading-healthcare-experts-team-up-to-accelerate-concussion-research-diagnosis-treatment-2013-03-11
TBI may quickly become even more a focus for AMBS than PD.
AMBS has had at least some connection with 2 of the 5 judges awarding these funds. Both Col. Jaime Grimes and retired Gen. Peter Chiarelli had a connection to the Banyan/AMBS clinical trials sponsored by the Dept of Defense in 2010 with positive results released last year.
AND a third judge, Dr. Geoff Manley was a featured speaker at last weeks TBI conference where AMBS and Banyan co-presented data.
What does it all mean? Nothing. Just proof that AMBS is mixing it up with and is on the right track to be a real player in this field. = one hell of a fantastic speculative investment with a lot going for it.
Great things coming...one schmo needed to pay his rent is all..
New contracts will bring the volume and these prices will be a thing of the past. Gettum' while you can...
Last chance for these 3's people ..this thing is gonna roll in last hour. I grabbed another 185k earlier...suggest you do the same..IMO
They're just trying to shake out the weak hands...no worries here...
Parkinsons=Big.. TBI=Maybe Even Bigger??
With all of the press in recent years about sports related concussions(both professional and school age).....
Add to that the TBI related injuries to veterans(DOD gave $23M to Banyan in 2010 to run the clinical trials that AMBS was a part of)
As much of a focal point that PD has been for this board regarding AMBS...Imagine the potential of a simple pin-prick diagnosis of Banyan to indicate damage paired with the tested beneficial application of AMBS to treat==Huge.
Today's SI report has everything to do with AMBS and Banyan's study.
http://sportsillustrated.cnn.com/more/news/20130307/new-blood-test-for-brain-damage/
You do remember that they are presenting together.... ....today......at the TBI conference, correct? .......?
Come on ...its exhausting throwing real facts, not rah-rah fluff, but real facts out with the same tired responses.
Banyan received a $26M DOD contract in 2010 to pursue TBI research....AMBS/Banyan study was part of that. Documented. Done. No mystery.
Once again for those in the cheap seats...
Documented timeline of Banyan and AMBS relationship.
Jan 2012 Amarantus is introduced to Banyan by the US Dept of Defense to pursue interests in identifying and treating brain trauma.
http://www.drugdiscoverynews.com/index.php?newsarticle=5717
June 2012 –AMBS and Banyan report that “"data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
http://content.stockpr.com/_news/amarantus/2012-06-07_Amarantus_BioSciences_and_Banyan_Biomarkers_Announ_13.pdf
Today Banyan AND AMBS have something to talk about at TBI conference???
http://www.tbiconference.com/home/speakers
...sounds like it to me. AMBS+Banyan=blood test and treatment for TBI!!
"Amarantus BioSciences Inc. (OTCBB:AMBS), Sunnyvale, Calif. Banyan Biomarkers Inc., Alachua, Fla. Business: Neurology Amarantus partnered with Banyan to develop Amarantus' mesencephalic astrocyte-derived neurotrophic"
LOL!!!The SI report has everything to do with AMBS and Banyan's study. You do remember that they are presenting together......today......at the TBI conference, correct? .......??
BanyanBio/AMBS TBI study mentioned in today's Sport Illustrated.com article!
http://sportsillustrated.cnn.com/more/news/20130307/new-blood-test-for-brain-damage/
Timeline to TBI Treatment- Banyan and AMBS
Jan 2012 Amarantus is introduced to Banyan by the US Dept of Defense to pursue interests in identifying and treating brain trauma.
http://www.drugdiscoverynews.com/index.php?newsarticle=5717
June 2012 –AMBS and Banyan report that “"data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
http://content.stockpr.com/_news/amarantus/2012-06-07_Amarantus_BioSciences_and_Banyan_Biomarkers_Announ_13.pdf
March 2013 Banyan AND AMBS have something to talk about at TBI conference???
http://www.tbiconference.com/home/speakers
...sounds like it to me. AMBS+Banyan=blood test and treatment for TBI!!
"Amarantus BioSciences Inc. (OTCBB:AMBS), Sunnyvale, Calif. Banyan Biomarkers Inc., Alachua, Fla. Business: Neurology Amarantus partnered with Banyan to develop Amarantus' mesencephalic astrocyte-derived neurotrophic"
And this grant funding and additional Dominion funding will make it possible.....big $$ is just beginning to come in!
"Received grant funding for a Traumatic Brain Injury collaboration with Banyan Biomarkers from Brewer Sports International;"
http://ih.advfn.com/p.php?pid=nmona&article=50239660
Go AMBS!!
Added a few more cheapies to my pile....time to get this train moving!
Good morning all! Feeling really good about today.
-Important conference this week continuing to share the word about MANF
-In the past few weeks AMBS has cleaned up the books and just this week dropped the dead-weight relationship with Rainbow.
-Look for big things in the near future!
HUGE VOLUME and HUGE POTENTIAL with Phase II testing. Someone just lit the fuse....
Woohoo.. I was afraid I missed the boat! Thank you weak hands for cheap shares....anything at this level is a gift. See you all at the pennies!
BOUNCE TIME!
RRRRRR/Not getting filled!!!
You see that crazy walk-down end of day yesterday? Big buyers are now locked and loaded...this thing is going to fly today...
Calling for a 20% gap at open...at least.
Thanks..BUT please go back and read my post and the attached info. It explains a lot more than your phone call to MJFF. Yesterday was the launch of the 2013 Fall funding cycle. The 2012 Fall to Spring 2013 is still in review....
Important- 2012/2013 MJFF Grant Still up for Grabs
Therapeutic Pipeline Program - Spring 2013
Deadline: Closed as of September 12, 2012. Now in Review.
*New* - Our flagship program for supporting critical preclinical and clinical development of promising Parkinson's therapies. An Edmond J. Safra Core Program for PD Research.- MJFF website
“Stage I proposals are required and should be clear and succinct while providing
sufficient details to allow a clear understanding on the science behind the
research project proposed. Stage I applications will be reviewed and a decision
will be made by the beginning of December of this year.
Invitations to apply for Stage II of the review process will be sent out no later
than mid-December 2012. At that time, the structure for this Second Stage
application will be provided. Stage II applications will be then due on February
6, 2013 and we will then take a month or so to review those applications and
expect to announce the awards in May 2013 and to begin funding the grantees in
June 2013.” https://www.michaeljfox.org/files/docs/tpp_conf_transcript.pdf
Read the bottom of the 3rd page.
It specifically says that there is a phase I and phase II approval for the funding and that a final award isn't announced until May 2013. The phase 1 termination and phase II invite deadline happens to coincides with the "retracted" PR last Fall that is so often referenced against AMBS. Final Stage II data was due February 6th, 2013......AMBS posted final results in PR February 4th and February 6th....coincidence?
Huge misunderstanding about the deadline yesterday...it was the opening of the Spring-Fall 2013 funded programs.... but the $10M grant money from MJFF new program launched last Fall 2012 is still up for grabs and won’t announce until May 2013.
Even if it goes to another worthy entry…..big pharma is just around the corner… Know what you own.